Provided by Tiger Trade Technology Pte. Ltd.

Recursion Pharmaceuticals, Inc.

4.27
-0.3600-7.78%
Post-market: 4.270.00000.00%19:59 EDT
Volume:40.73M
Turnover:178.49M
Market Cap:2.28B
PE:-4.18
High:4.60
Open:4.51
Low:4.23
Close:4.63
52wk High:7.18
52wk Low:2.77
Shares:535.00M
Float Shares:522.33M
Volume Ratio:0.98
T/O Rate:7.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0219
EPS(LYR):-1.4410
ROE:-56.58%
ROA:-27.33%
PB:2.50
PE(LYR):-2.96

Loading ...

Recursion Pharmaceuticals - Extends Agreement Term from Five to Six Years - SEC Filing

THOMSON REUTERS
·
Sep 21

Recursion’s REC-7735 Trial: Early Precision Oncology Data That Could Move RXRX

TIPRANKS
·
Sep 18

Analysts Have Conflicting Sentiments on These Healthcare Companies: Recursion Pharmaceuticals (RXRX), Teladoc (TDOC) and Oscar Health (OSCR)

TIPRANKS
·
Sep 16

Recursion Pharma CEO Najat Khan Sells 22,408 Shares for $78,822

Reuters
·
Sep 11

Arm's Haas: AI Could Cure Cancer In Our Lifetime — If The Industry Can Build Enough Chips

AI Industry Frontlines
·
Sep 08

Recursion Pharma Director Blake Borgeson Disposes of 30,000 Shares Valued at $100,200

Reuters
·
Sep 03

Nvidia Earnings: Six Signals That Matter for the AI Supply Chain

Earnings Spotlight
·
Aug 26

US Tech Stocks Sell Off Ahead of Nvidia Earnings

Bellwether Stocks Movement
·
Aug 25

Nvidia Faces Major Test This Week as AI Market's Bellwether

Bellwether Stocks Movement
·
Aug 24

Nvidia Q2 FY27 Earnings: Gross Margin, Q3 Guidance in Focus

Bellwether Stocks Movement
·
Aug 21

Contineum, Disc Medicine, Recursion Advance Pipelines Ahead of Catalysts, Morgan Stanley Says

MT Newswires Live
·
Aug 17

Morgan Stanley Adjusts PT on Recursion Pharmaceuticals to $5.30 From $5.50, Keeps Equalweight Rating

MT Newswires Live
·
Aug 17

Recursion Director Blake Borgeson Disposes of 30,000 Shares for $97,500

Reuters
·
Aug 07

Primer: Recursion Pharmaceuticals (RXRX US) - Aug 2026

Smartkarma
·
Aug 06

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Geron (GERN), Zimmer Biomet Holdings (ZBH) and Recursion Pharmaceuticals (RXRX)

TIPRANKS
·
Aug 06

Recursion Pharmaceuticals, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 05

Recursion Q2 2026 earnings: Expense cuts narrow the net loss

TradingKey
·
Aug 05

Earnings Flash (RXRX) Recursion Pharmaceuticals Posts Q2 Loss $0.25 a Share, vs. FactSet Est of $0.28 Loss

MT Newswires Live
·
Aug 05

Recursion Pharmaceuticals Q2 Operating Revenue USD 7.303 Million Vs. IBES Estimate USD 11.9 Million

Reuters
·
Aug 05

Recursion Pharmaceuticals Q2 Revenue Misses Estimates, Cuts 2026 Expense Outlook

Reuters
·
Aug 05